|
|
 |
|
|
Biotechnology, while being acknowledged as an emerging and exciting science for the development of therapeutic and preventative pharmaceuticals, is also recognized as being relatively more risky compared to traditional pharmaceutical technologies. Since it is also well recognized that biotech product development has a long gestation period with heavy investments but has the potential for high returns, Transgene Biotek has adopted a model to mitigate the risk while working on a list of potential blockbuster drugs. One of the keys to this is combining the relatively low-hanging fruit of bio-generic drugs with truly cutting edge technology products.
TBL’s basic rules for selecting and marketing technologies
- TBL does not undertake fundamental research such as development of new molecules.
- TBL considers only those technologies where the drugs of interest have already been developed to a basic degree, and proven at least to the extent of in-vitro efficacy. It is considered a bonus when, in several cases, they have been tried successfully even in minimal animal trials.
- TBL does not enter into retail marketing of any product on its own. For marketing, it employs a two pronged strategy.
- In case of cutting edge technologies, each one will be out-licensed to a global pharma major at the end of Phase I/II human clinical trials.
- In case of bio-generics, the products will be marketed through strategic alliances in different geographic locations while TBL may market on its own in certain territories.
|
|
|
|
|
|
|
|
